BioLife Solutions (NASDAQ:BLFS) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of BioLife Solutions (NASDAQ:BLFS) from a buy rating to a strong-buy rating in a research report report published on Thursday, BidAskClub reports.

BLFS has been the subject of several other research reports. Maxim Group set a $26.00 price target on shares of BioLife Solutions and gave the company a buy rating in a research report on Tuesday, September 17th. Zacks Investment Research lowered shares of BioLife Solutions from a buy rating to a hold rating in a research report on Wednesday, October 30th. Northland Securities increased their price target on shares of BioLife Solutions from $18.00 to $22.00 and gave the company an outperform rating in a research report on Wednesday, September 4th. HC Wainwright assumed coverage on shares of BioLife Solutions in a research report on Monday, July 22nd. They set a buy rating and a $23.00 price target for the company. Finally, ValuEngine upgraded shares of BioLife Solutions from a sell rating to a hold rating in a research report on Friday, October 25th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $19.20.

Shares of BLFS stock traded down $0.03 on Thursday, hitting $16.73. The stock had a trading volume of 125,819 shares, compared to its average volume of 172,762. The business has a 50 day moving average of $16.92 and a 200 day moving average of $17.76. The stock has a market cap of $384.52 million, a price-to-earnings ratio of 119.50 and a beta of 1.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.42 and a quick ratio of 7.71. BioLife Solutions has a 12-month low of $9.15 and a 12-month high of $22.44.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The company had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.59 million. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. As a group, research analysts expect that BioLife Solutions will post 0.08 earnings per share for the current fiscal year.

In other BioLife Solutions news, CFO Greef Roderick De sold 10,000 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $17.08, for a total transaction of $170,800.00. Following the completion of the transaction, the chief financial officer now owns 35,859 shares in the company, valued at $612,471.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Rice sold 9,905 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $18.07, for a total transaction of $178,983.35. Following the transaction, the chief executive officer now owns 184,919 shares of the company’s stock, valued at approximately $3,341,486.33. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 197,556 shares of company stock valued at $3,720,974. 27.00% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the business. Alpine Woods Capital Investors LLC boosted its position in BioLife Solutions by 9.0% during the third quarter. Alpine Woods Capital Investors LLC now owns 10,900 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 900 shares during the period. Morgan Stanley boosted its position in BioLife Solutions by 17.5% during the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 1,713 shares during the period. JPMorgan Chase & Co. bought a new position in BioLife Solutions during the second quarter worth about $30,000. Invesco Ltd. boosted its position in BioLife Solutions by 4.7% during the second quarter. Invesco Ltd. now owns 81,319 shares of the medical equipment provider’s stock worth $1,378,000 after purchasing an additional 3,669 shares during the period. Finally, Northern Trust Corp boosted its position in BioLife Solutions by 9.9% during the second quarter. Northern Trust Corp now owns 50,959 shares of the medical equipment provider’s stock worth $863,000 after purchasing an additional 4,600 shares during the period. Hedge funds and other institutional investors own 45.19% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: What is the 52-week high/low?

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.